Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA nod for Omniwave thrombus removing technology:

This article was originally published in Clinica

Executive Summary

Omnisonics Medical Technologies has received 510(k) clearance from the US FDA for its thrombus-removing OmniWave Endovascular System. The catheter-based system is used for the infusion of specific liquids, including thrombolytics, and to eradicate thrombi in the peripheral vasculature. It works by delivering low-power, transverse ultrasonic energy to remove thrombus "quickly, safely and effectively", said the Wilmington, Massachusetts firm. Thrombi are a common problem, with deep vein thrombosis (DVT) affecting approximately two million people in the US each year, and acute limb ischaemia affecting some 250,000. The OmniWave technology has been available in Europe since 2002.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049957

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel